ライフサイエンスコーパス: intrahepatic

1 (SUV) analysis was performed, and the total intrahepatic (18)F-fluoroethylcholine positive tumor vol

2 VAT (-22%), intrahepatic (-29%), and intrapericardial (-11%) fats de

3 sed case-control study, 2395 CCA cases (1169 intrahepatic, 995 perihilar, and 231 distal) seen at the

4 t that abnormal AAT protein conformation and intrahepatic accumulation have broad effects on metaboli

5 e and hepatic steatosis, consistent with the intrahepatic accumulation of glucocorticoids, and predis

6 lectrin-mediated cross-presentation supports intrahepatic adaptive antiviral immune responses and may

7 Moreover, the renal excretion kinetic and intrahepatic albumin binding affinity of CyG can further

8 Statistical analysis to compare intrahepatic and blood NK cell receptor expression inclu

9 We aimed to compare intrahepatic and blood NK cell receptor expression to de

10 was associated with decreased activation of intrahepatic and blood NK cells; it was followed by rest

11 Intrahepatic and circulating lymphocytes were extracted;

12 ility of invasion and migration in vitro and intrahepatic and distal lung metastasis in vivo of HCC c

13 elial cells, named cholangiocytes, that line intrahepatic and extrahepatic bile ducts, contribute sub

14 ession levels were measured in the following intrahepatic and extrahepatic cholangiocarcinoma (CCA) c

15 ghtly controlled event involving coordinated intrahepatic and extrahepatic regulation.

16 ance (tolerance tests) were achieved in both intrahepatic and intraomental sites in rats.

17 As part of a prospective trial, the intrahepatic and intrapulmonary stability of 2 albumin c

18 gh the CSC profile was similar between mucin-intrahepatic and mucin-perihilar subtypes, CD13(+) CSCs

19 erosing cholangitis was associated with both intrahepatic and perihilar CCA, with similar AORs of 14.

20 in centers from Asia were more likely to be intrahepatic and were less frequently invasive compared

21 cular density, portosystemic shunting (PSS), intrahepatic angiogenesis, and fibrosis without affectin

22 itial activation, but was maintained by high intrahepatic antigen load during the early phase of the

23 han perihilar (AOR = 2.9, 95% CI 2.2-3.8) or intrahepatic (AOR = 2.5, 95% CI 2.0-3.2) CCA.

24 h perihilar (AOR = 453, 95% CI 104-999) than intrahepatic (AOR = 93.4, 95% CI 27.1-322) or distal (AO

25 Group 1 rats received intrahepatic arterial injection of PEG-HAuNS and ethiodi

26 activation and spontaneous IgG production by intrahepatic B cells.

27 erozygous mice (Jag1(+/-) ) exhibit impaired intrahepatic bile duct (IHBD) development, decreased SOX

28 Preoperative knowledge of intrahepatic bile duct (IHD) anatomy is critical for pla

29 Intrahepatic bile duct anatomy is complex with many comm

30 of cirrhotic patients with tumors exhibiting intrahepatic bile duct differentiation remains controver

31 opment of strategies to block progression of intrahepatic bile duct injury in patients with BA.

32 ed hepatic IL-17A production and ameliorated intrahepatic bile duct injury.

33 llowing bile duct ligation (BDL), increasing intrahepatic bile duct mass (IBDM) and fibrosis.

34 ry proliferation was evaluated by changes in intrahepatic bile duct mass and the expression of prolif

35 Treatment with GnRH increased intrahepatic bile duct mass as well as proliferation and

36 ivo and in vitro knockdown of GnRH decreased intrahepatic bile duct mass/cholangiocyte proliferation

37 hepatoblasts into cholangiocytes, premature intrahepatic bile duct morphogenesis, and biliary hyperp

38 While intrahepatic bile duct proliferation is universal at dia

39 ithout these infections: cancer of liver and intrahepatic bile duct; fibrosis, cirrhosis, and other l

40 adolinium administration = 1 x dilatation of intrahepatic bile ducts + 2 x dysmorphy + 1 x portal hyp

41 the characteristic phenotype of high-density intrahepatic bile ducts and enlarged liver in Rosa(NICD/

42 Small and large intrahepatic bile ducts consist of small and large chola

43 bile ducts, and its expression is reduced in intrahepatic bile ducts of patients with cholestatic dis

44 Adjacent intrahepatic bile ducts were dilated.

45 isease characterised by destruction of small intrahepatic bile ducts, leading to fibrosis and potenti

46 biliary glands within extrahepatic and large intrahepatic bile ducts.

47 uction of the extrahepatic biliary tract and intrahepatic bile ducts.

48 ompensatory proliferation of hepatocytes and intrahepatic biliary cells, thus impeding HCC developmen

49 Nineteen patients with intrahepatic biliary cystadenomas and two patients with

50 mixtures found in primary cultures of human intrahepatic biliary epithelial cells (HiBEC), human ren

51 , human bronchial epithelial cells, isolated intrahepatic biliary epithelial cells from explanted pri

52 phocyte responses orchestrate progression of intrahepatic biliary injury in this disease.

53 nd HuH-28, as well as the nonmalignant human intrahepatic biliary line, H69.

54 inistration of GnRH to normal rats increased intrahepatic biliary mass (IBDM) and hepatic fibrosis.

55 in increased cholangiocyte proliferation and intrahepatic biliary mass, liver damage, and inflammatio

56 the clinico-radiological characteristics of intrahepatic biliary mucinous cystic neoplasms and to es

57 Intrahepatic biliary mucinous cystic neoplasms are rare

58 Intrahepatic biliary mucinous cystic neoplasms are rare

59 e produced a crowded branching defect in the intrahepatic biliary network and influenced actin dynami

60 ase 5 (Cdk5) led to reduced branching in the intrahepatic biliary network in zebrafish.

61 The intrahepatic biliary network is a highly branched three-

62 insights into branching morphogenesis of the intrahepatic biliary network.

63 The pathogenesis of intrahepatic biliary stricture formation in patients wit

64 Our primary outcome was development of intrahepatic biliary strictures consistent with IC.

65 th 2% SPIO can quantitatively depict in vivo intrahepatic biodistribution in a rat model.

66 This was associated with intrahepatic but not circulating glucocorticoid excess,

67 limp-1(hi)Hobit(lo) T cells found within the intrahepatic but not the circulating memory CD8 T cell p

68 olesterolemia induced the differentiation of intrahepatic, but not intrasplenic, Th17 cells in wild-t

69 zation of these pathways was sought in human intrahepatic CC, in vivo, using multiplex labeling and s

70 iated with shorter survival of patients with intrahepatic CCA (HR, 4.2; 95% CI: 1.1-14.1; P = 0.04).

71 NAFLD and CCA, stratifying by its subtypes; intrahepatic CCA (iCCA), and extrahepatic CCA (eCCA).

72 Noninvasive differential diagnosis between intrahepatic CCA and hepatocellular carcinoma (HCC) is s

73 0.904 for HCC versus control, and 0.894 for intrahepatic CCA versus HCC.

74 Clearances of intrahepatic cccDNA and/or HBsAg are critical endpoints

75 tabolism in NAFLD causes a selective loss of intrahepatic CD4(+) but not CD8(+) T lymphocytes, leadin

76 increased frequency of IL-17(+) cells among intrahepatic CD4(+) T cells and higher Th17/rTreg and Th

77 arked by an increase in IL-17(+) cells among intrahepatic CD4(+) T cells.

78 almitic acid, and mediates selective loss of intrahepatic CD4(+) T lymphocytes.

79 Liver disease elicits alterations in the intrahepatic CD4(+) T-cell compartment that suppress T-c

80 in 10), which correlated with populations of intrahepatic CD4+ T cells (CD45RO+PD-1+).

81 s were increased and hyperproliferative, the intrahepatic CD4/CD8 ratio was decreased.

82 Human intrahepatic CD49a(+) NK cells express killer cell Ig-li

83 HCV-specific intrahepatic CD8(+) T cells from patients with chronic H

84 ls and expression of inhibitory molecules on intrahepatic CD8(+) T cells.

85 Exhausted intrahepatic CD8(+) T-cell targeting-conserved epitopes

86 Existing intrahepatic CD8+ T cells targeting dominant epitopes of

87 infection can be attributed to nonfunctional intrahepatic CD8+ T-cell responses.

88 Intrahepatic cell-derived, early IL-17 is important for

89 7F secretion in vitro and in vivo; IL-17F(+) intrahepatic cells expanded more vigorously in IL-17A kn

90 Seven patients had nodules demonstrating intrahepatic cholangiocarcinoma (I-CCA), nine had I-CCA

91 Intrahepatic cholangiocarcinoma (ICC) and hepatocellular

92 Curative treatment of intrahepatic cholangiocarcinoma (ICC) and hilar cholangi

93 rom combined hepatocellular liver cancer and intrahepatic cholangiocarcinoma (ICC) has increased and

94 We aimed to examine the burden of intrahepatic cholangiocarcinoma (ICC) in Thailand and id

95 Intrahepatic cholangiocarcinoma (ICC) is a highly malign

96 In patients with intrahepatic cholangiocarcinoma (ICC), the oncologic ben

97 on and aggressive malignancy of mass-forming intrahepatic cholangiocarcinoma (ICC), we modeled ICC de

98 to induce hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).

99 Intrahepatic cholangiocarcinoma (iCCA) is a fatal bile d

100 er comprises hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and other rare t

101 Standard therapies for localized inoperable intrahepatic cholangiocarcinoma (IHCC) are ineffective.

102 e to enrich for cell surface proteins of the intrahepatic cholangiocarcinoma cell line CC-SW-1 was de

103 ondary glioblastoma, acute myeloid leukemia, intrahepatic cholangiocarcinoma, and chondrosarcomas, le

104 cers, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, are leading causes of c

105 ly encompassing hepatocellular carcinoma and intrahepatic cholangiocarcinoma, has become the second l

106 % were hepatocellular carcinoma and 20% were intrahepatic cholangiocarcinoma.

107 llular carcinoma with stem cell features and intrahepatic cholangiocarcinoma.

108 102 hepatocellular carcinomas (HCCs), three intrahepatic cholangiocarcinomas (ICCs), one neuroendocr

109 soforms 1 or 2 occur in approximately 15% of intrahepatic cholangiocarcinomas.

110 itized both EHCs and the otherwise resistant intrahepatic cholangiocytes to the toxin, whereas replen

111 inotransferase (1239 vs 2065 U/L, P = 0.02), intrahepatic cholangiopathy (0% vs 22%, P = 0.015), bili

112 No graft failure due to intrahepatic cholangiopathy or nonfunction occurred in H

113 before procurement causes injuries including intrahepatic cholangiopathy, which may lead to graft los

114 c cholestasis; BRIC) to progressive familial intrahepatic cholestasis (PFIC).

115 uestration, viral hepatitis, and sickle cell intrahepatic cholestasis (SCIC).

116 holangiopathies such as progressive familial intrahepatic cholestasis and primary sclerosing cholangi

117 diagnosis, 14 age-appropriate subjects with intrahepatic cholestasis as diseased controls and seven

118 idered as an additional progressive familial intrahepatic cholestasis gene.

119 Intrahepatic cholestasis of pregnancy (ICP) affects 1/14

120 nagement and pregnancy outcome in women with intrahepatic cholestasis of pregnancy (ICP) and treatmen

121 Intrahepatic cholestasis of pregnancy (ICP) is a pregnan

122 Intrahepatic cholestasis of pregnancy (ICP) is a pregnan

123 Intrahepatic cholestasis of pregnancy (ICP) is associate

124 pruritus of the skin is an early symptom of intrahepatic cholestasis of pregnancy (ICP) or due to be

125 ow-phospholipid-associated cholelithiasis or intrahepatic cholestasis of pregnancy.

126 Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a result of m

127 f clinical evolution in progressive familial intrahepatic cholestasis type 2 patients and how they re

128 rea cycle disorders and progressive familial intrahepatic cholestasis type 2.

129 cluded 22 children with progressive familial intrahepatic cholestasis type 2.

130 ously in a patient with progressive familial intrahepatic cholestasis type 3 (PFIC-3).

131 ary diseases, including progressive familial intrahepatic cholestasis type 3 (PFIC3), a rare disease

132 Progressive familial intrahepatic cholestasis type 3 is caused by biallelic v

133 ariations identified in progressive familial intrahepatic cholestasis type 3 patients.

134 kout mouse, a model for progressive familial intrahepatic cholestasis type 3.

135 tations in ATP8B1 cause progressive familial intrahepatic cholestasis type1 in humans, which is chara

136 hildhood liver disease, progressive familial intrahepatic cholestasis, but cause and effect is less c

137 fferent genes can cause progressive familial intrahepatic cholestasis, but known genes cannot account

138 In a mouse model of intrahepatic cholestasis, metformin treatment induced FX

139 h Alagille syndrome (ALGS), 16 with familial intrahepatic cholestasis-1 (FIC1), 18 with bile salt exp

140 asis characterized by a progressive familial intrahepatic cholestasis-like phenotype with normal seru

141 s in five patients with progressive familial intrahepatic cholestasis-like phenotype with normal seru

142 ysis of nontransplant surgical approaches to intrahepatic cholestasis.

143 spectrum from intermittent (benign recurrent intrahepatic cholestasis; BRIC) to progressive familial

144 Hepatitis C virus (HCV) modulates intrahepatic cholesterol biosynthetic pathways to promot

145 Subsequently, intrahepatic colorectal cancer metastases were generated

146 andheld imaging device was then performed on intrahepatic colorectal metastases after the administrat

147 al and malignant tissue in a murine model of intrahepatic colorectal metastasis.

148 of murine liver with adenovirus, a model for intrahepatic cross-presentation, confirms hepatocytes di

149 tment hour 10 (P = .023) and peak (P = .034) intrahepatic CXCL10 levels were also higher in these pat

150 eatment hour 6 and day 2, while induction of intrahepatic CXCL10 mRNA peaked (mean fold-induction [+/

151 patic tumors and account for less than 5% of intrahepatic cystic lesions.

152 , indicating a steady state of pulmonary and intrahepatic degradation.

153 ers by RNA interference resulted in impaired intrahepatic development.

154 Very little is known about the intrahepatic distribution of HBV cccDNA in infected pati

155 Portal venous pressure and intrahepatic endothelial dysfunction might account for t

156 ebrand factor antigen levels as a marker for intrahepatic endothelial dysfunction.

157 In unpaired EOT liver biopsies, intrahepatic expression of fatty acid metabolism and lip

158 examined changes in serum lipid profiles and intrahepatic expression of lipid-related genes during in

159 , and the GCKR rs1260326 SNPs in determining intrahepatic fat accumulation (P < 0.05).

160 o the adipose tissue and the liver regulates intrahepatic fat storage.

161 ther adjusted for weight loss, losing VAT or intrahepatic fat was independently associated with impro

162 Body fat and intrahepatic fat were detected by magnetic resonance ima

163 eased hepatic de novo lipogenesis, decreased intrahepatic fatty acid oxidation, and inadequate increa

164 nt was also associated with replenishment of intrahepatic glucose due to enhanced gluconeogenesis and

165 in vitro knockdown of TTK effectively blocks intrahepatic growth of human HCC xenografts.

166 Lower intrahepatic HBV pregenomic RNA levels and 25 predictive

167 upport the prognostic importance of treating intrahepatic HCC even in patients with metastatic diseas

168 ular carcinoma (HCC) is mainly determined by intrahepatic HCC progression, local treatment with TACE

169 essful treatment options, several aspects of intrahepatic HCV infection dynamics are still poorly und

170 The intrahepatic HCV-specific CD8+ T-cell repertoire establi

171 INT-747), a potent selective FXR agonist, on intrahepatic hemodynamic dysfunction and signaling pathw

172 infection, during or shortly before maximal intrahepatic IFN-stimulated gene expression, but disappe

173 clearance of HCV is associated with loss of intrahepatic immune activation by IFNalpha, which is ind

174 cells as important "first responders" of the intrahepatic immune environment.

175 e important causes of human disease, but the intrahepatic immune response to hepatitis viruses is poo

176 ge of TCPTP by NS3/4A induces a shift of the intrahepatic immune response toward a nonantiviral Th2-d

177 nic hepatitis C virus infection activates an intrahepatic immune response, leading to increased expre

178 gt1 and gt3 infections do not elicit innate intrahepatic immune responses and remain highly sensitiv

179 gitis virus (LCMV) clone 13, on early innate intrahepatic immune responses in mice.

180 ms of liver tolerance limit the magnitude of intrahepatic immune responses, allowing the liver to rec

181 The intrahepatic immunity of wild-type and NS3/4A-transgenic

182 n of the nonstructural (NS)3/4A protease, on intrahepatic immunity.

183 Intrahepatic implantation of mouse HCC cell lines requir

184 , we postulated that Mincle signaling drives intrahepatic inflammation and liver injury in Con A hepa

185 In fact, intrahepatic inflammatory monocytes are skewed toward a

186 hat inflammatory monocytes contribute to the intrahepatic inflammatory response during the early phas

187 RIF) was a central mediator of the resulting intrahepatic inflammatory response that was independent

188 n vitro or in xenografted mice after s.c. or intrahepatic injection in normal and cirrhotic (carbon t

189 Herein, we describe an original method of intrahepatic injection into adult NOD.Cg-Prkdc(scid)Il2r

190 t of severe amebic liver abscesses following intrahepatic injection of E. histolytica by a combined r

191 Intrahepatic injection of HB cell lines leads to liver t

192 -mediated clearance of senescent cells after intrahepatic injection of NRAS (Figures 2I, 3B, 3C, and

193 ormed on HCC model implanted in nude mice by intrahepatic injection.

194 AxC-Irish (ACI) rats were given intrahepatic injections of rat hepatoma cells (H4IIE); 2

195 iled to induce viremia in tamarins following intrahepatic inoculation, nor did they lead to progeny v

196 EV infections in humanized mice and modelled intrahepatic interferon stimulated gene (ISG) responses.

197 s superior to the low-fat diet in decreasing intrahepatic, intrapericardial, and pancreatic fats (P<0

198 lycemia, these results provide evidence that intrahepatic islet transplantation can restore glucose c

199 rpose of this study was to determine whether intrahepatic islet transplantation improves endogenous g

200 , disease duration before and 6 months after intrahepatic islet transplantation using stepped hyperin

201 prerequisite is currently incompatible with intrahepatic islet transplantation.

202 flow during respiration in the upper part of intrahepatic IVC proximal to a large collateral vein as

203 Intrahepatic KCs were HBsAg positive and more activated

204 Twenty-nine patients revealed 53 intrahepatic lesions.

205 crosis factor alpha and interleukin 2 at the intrahepatic level significantly more than HCV-specific

206 onsiveness to IFNalpha therapy, as are lower intrahepatic levels of HBV pregenomic RNA and pre-activa

207 e remaining macrophages, resulted in reduced intrahepatic levels of proinflammatory cytokines.

208 ally, the lack of stabilin-1 led to elevated intrahepatic levels of the profibrogenic chemokine CCL3

209 Intrahepatic lipid (IHL) and intramyocellular lipid (IMC

210 antly greater visceral adipose tissue (VAT), intrahepatic lipid (IHL), plasma free fatty acids, adipo

211 estriction to allow an effective decrease of intrahepatic lipid component, and despite that evidence

212 Intrahepatic lobe shunting was present on NMI in only 2.

213 For colorectal liver metastasis (CRLM), intrahepatic lymph invasion and lymph node metastasis ar

214 Furthermore, when splenic and intrahepatic lymphocytes from IFN-alpha- and IL-15-treat

215 FACS analysis was performed on PBMCs and intrahepatic lymphocytes.

216 ) iMPhi by the CCL2 inhibitor, mNOX-E36, the intrahepatic macrophage equilibration shifted toward the

217 th sofosbuvir and velpatasvir, we found that intrahepatic MAIT cells are activated by monocyte-derive

218 re further supported by the analysis of such intrahepatic markers of WHV infection as replicative int

219 n results in rapid changes in peripheral and intrahepatic metabolic pathways, implicating a direct ef

220 hat implicate a role for GKRP in maintaining intrahepatic metabolite homeostasis.

221 LOXL2 promoted intrahepatic metastasis by increasing tissue stiffness,

222 In hepatocellular carcinoma (HCC), intrahepatic metastasis frequently correlates with epith

223 icantly reduced CCA cell growth in vitro and intrahepatic metastasis in vivo.

224 ens, especially in portal vein metastasis or intrahepatic metastasis, compared to normal tissues.

225 Our findings suggest that the intrahepatic microenvironment is highly enriched with pr

226 oavailability, HSC deactivation, and reduced intrahepatic microthrombosis.

227 educed fibrin deposition, suggesting reduced intrahepatic microthrombosis.

228 sence of a likely human counterpart of mouse intrahepatic NK cells with adaptive-like features.

229 elected patients with perihilar but not with intrahepatic or distal cholangiocarcinoma.

230 omas (CCAs) comprise a mucin-secreting form, intrahepatic or perihilar, and a mixed form located peri

231 transcriptome analysis of a large number of intrahepatic, perihilar and distal cholangiocarcinomas a

232 0.27-0.42), and 0.29 (95% CI 0.19-0.44) for intrahepatic, perihilar, and distal CCA, respectively (P

233 arcinomas of different anatomical locations (intrahepatic, perihilar, and distal).

234 nd pharmacologic measures, with transjugular intrahepatic portal-systemic shunt (TIPS) performed when

235 e the feasibility and safety of transjugular intrahepatic portosystemic shunt (TIPS) as a treatment f

236 <12 mm Hg after placement of a transjugular intrahepatic portosystemic shunt (TIPS) correlates with

237 early liver failure (ELF) after transjugular intrahepatic portosystemic shunt (TIPS) creation in pati

238 e efficacy and complications of transjugular intrahepatic portosystemic shunt (TIPS) creation perform

239 covered stent and bare stent in transjugular intrahepatic portosystemic shunt (TIPS) for cirrhotic po

240 hnical success, and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) in a series of p

241 The efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) in this populati

242 tic blood flow before and after transjugular intrahepatic portosystemic shunt (TIPS) placement.

243 veloped PV recanalization (PVR)-transjugular intrahepatic portosystemic shunt (TIPS) to potentiate LT

244 ta are available on the role of transjugular intrahepatic portosystemic shunt (TIPS) with covered ste

245 commonly used for creation of a transjugular intrahepatic portosystemic shunt (TIPS).

246 T) has been mainly treated with transjugular intrahepatic portosystemic shunt (TIPS).

247 ortality in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS).

248 ative portal vein embolization, transjugular intrahepatic portosystemic shunt placement, balloon retr

249 controversy over the ability of transjugular intrahepatic portosystemic shunts (TIPS) to increase sur

250 controversy over the ability of transjugular intrahepatic portosystemic shunts (TIPS) to increase sur

251 ) can be effectively treated by transjugular intrahepatic portosystemic stent shunt (TIPS).

252 to groups given a small covered transjugular intrahepatic portosystemic stent-shunt (TIPS) (8 mm; n =

253 6; HR, 0.15; 95% CI, 0.03-0.69), and time to intrahepatic progression (P = 0.010; HR, 0.16; 95% CI, 0

254 2 largest liver metastases predicted time to intrahepatic progression (P = 0.013; HR, 0.21; 95% CI, 0

255 ival, progression-free survival, and time to intrahepatic progression after radioembolization for liv

256 ival, progression-free survival, and time to intrahepatic progression were among other factors correl

257 unlabeled lipiodol) could reduce the rate of intrahepatic recurrence at 2 y.

258 roscopic RFA (L-RFA) have been used to treat intrahepatic recurrent small hepatocellular carcinoma (H

259 erved that hypercholesterolemia elevated the intrahepatic regulatory T (Treg) cell population and inc

260 c infection, characterized by high levels of intrahepatic regulatory T cells and expression of inhibi

261 CC in male mice with substantially increased intrahepatic retention of hydrophobic BAs and decreased

262 ant cholestasis with substantially increased intrahepatic retention of hydrophobic BAs.

263 However, intrahepatic RNA inoculation of a horse initiated infect

264 ables were compared between tumors that were intrahepatic, small (<7 cm), and solitary (ISS) and thos

265 iRNAs to already tumor-bearing liver, limits intrahepatic spread of liver cancer cells.

266 ic cholangiopathy (IC), a disease of diffuse intrahepatic stricturing limits broader DCDD use.

267 ary stricture, of which 88 (11.8%) exhibited intrahepatic structuring consistent with IC.

268 en primary human cholangiocytes and isolated intrahepatic T cells ex vivo and in vivo using the Ova-b

269 ot CD160, TIM-3, or LAG-3) were increased on intrahepatic T cells from healthy and diseased liver tis

270 Flow cytometry of intrahepatic T cells isolated from liver biopsy led to t

271 id not induce a predominant Th17 response in intrahepatic T cells, given that hepatic cremtg CD4+ T c

272 ults elucidate a new mechanism that controls intrahepatic T-cell differentiation during atheroscleros

273 n hypercholesterolemic Ldlr(-/-) mice led to intrahepatic Th1 cell differentiation and CD11b(+)CD11c(

274 Intrahepatic transcatheter infusion procedures were perf

275 However, relative to the conventional intrahepatic transplantation site, the subcutaneous site

276 ys, a number comparable to that required for intrahepatic transplantation; in the absence of oxygen t

277 Though intrahepatic Treg numbers were increased and hyperprolif

278 ected 4 years after HCV clearance shows that intrahepatic Tregs are still present in all patients, su

279 s independently associated with the level of intrahepatic triacylglycerol (r = 0.53; P = .007).

280 The cut-off point of intrahepatic triglyceride (IHTG) content to define nonal

281 ciated with insulin resistance and increased intrahepatic triglyceride (IHTG) content, both of which

282 eks or a eucaloric control diet and measured intrahepatic triglyceride content (IHTG) using proton ma

283 ma Fgf21 level significantly correlated with intrahepatic triglyceride content.

284 eight gain is associated with an increase in intrahepatic triglycerides (IHTGs), and is the primary c

285 In metastatic HCC, treatment of intrahepatic tumor by TACE may be associated with improv

286 antibody against GPC3 ((89)Zr-alphaGPC3) for intrahepatic tumor localization using PET.

287 CI: 18, 47) of 40 completely ablated tumors, intrahepatic tumor recurrence was observed at 2-18 month

288 nths on average to assess complete ablation, intrahepatic tumor recurrence, and complications.

289 of (90)Y radioembolization in patients with intrahepatic tumors from pretherapeutic baseline paramet

290 Patients with multiple intrahepatic tumors or poor liver function and no major

291 MRI showed large intrahepatic tumors with active neovascularization.

292 nts, which were mainly mediated by increased intrahepatic tumour-growth factor (TGF)-beta because blo

293 Human intrahepatic TVR concentration, measured for the first t

294 lular mechanisms that regulate the increased intrahepatic vascular resistance (IHVR) in cirrhosis.

295 In cirrhosis, increased intrahepatic vascular resistance (IHVR) is the primary f

296 n contributes significantly to the increased intrahepatic vascular resistance that is the primary cau

297 FXR expression and involved intrahepatic vasoactive pathways (e.g., endothelial nitr

298 l resolution provides a means for monitoring intrahepatic virological events in chronic HBV infection

299 r subtypes, CD13(+) CSCs characterized mixed-intrahepatic, whereas LGR5(+) characterized mucin-CCA su

300 By contrast, in intrahepatic xenografts in cirrhotic livers, tumors were